文献速递乳腺癌

口服紫杉醇联合Encequidar对比静脉紫杉醇治疗转移性乳腺癌的开放标签随机多中心III期研究

Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
PubMed 文献 · J Clin Oncol · 2022-07-20

这项开放标签III期研究将402例转移性乳腺癌患者按2:1随机分配至口服紫杉醇联合Encequidar组(265例)或静脉紫杉醇组(137例)。口服组确认缓解率为36%,静脉组为23%(P=0.01);无进展生存期分别为8.4个月和7.4个月,总生存期分别为22.7个月和16.5个月。口服组神经病变和脱发发生率较低,但恶心、呕吐、腹泻及中性粒细胞减少并发症更多。

要点

  • 口服紫杉醇联合Encequidar组确认缓解率36%,静脉紫杉醇组23%,差异有统计学意义(P=0.01)。
  • 口服组神经病变(>2级)发生率2%,静脉组15%;脱发(所有级别)发生率49%对62%。
  • 基线肝酶升高的患者接受口服方案时易出现早期中性粒细胞减少和严重感染。

核心结论

  • 口服紫杉醇联合Encequidar较静脉紫杉醇提高了确认的肿瘤缓解率,无进展生存期和总生存期呈现趋势。
  • 口服组神经病变发生率和严重程度较低,但中性粒细胞减少性严重感染增加。
  • 基线肝酶升高使口服紫杉醇联合Encequidar患者易出现早期中性粒细胞减少和严重感染。

研究设计与样本

  • 开放标签、随机、多中心III期研究,比较口服紫杉醇联合Encequidar与静脉紫杉醇。
  • 口服组方案:紫杉醇205 mg/m2联合Encequidar甲磺酸盐一水合物15 mg,每周连续3天。
  • 静脉组方案:紫杉醇175 mg/m2,每3周一次。
  • 入组患者为转移性乳腺癌女性,器官功能充足,距末次紫杉烷治疗至少1年,按2:1随机分配至口服组或静脉组。
  • 共入组402例来自拉丁美洲的患者(口服组265例,静脉组137例),人口学特征和既往治疗均衡。

主要发现

  • 确认缓解率(意向性治疗分析)口服组36% vs 静脉组23%(P=0.01)。
  • 无进展生存期口服组8.4个月 vs 静脉组7.4个月(风险比0.768;95.5%CI 0.584至1.01;P=0.046)。
  • 总生存期口服组22.7个月 vs 静脉组16.5个月(风险比0.794;95.5%CI 0.607至1.037;P=0.08)。
  • 3-4级不良反应发生率口服组55% vs 静脉组53%。
  • 口服组神经病变(>2级)发生率2% vs 静脉组15%;脱发(所有级别)发生率49% vs 62%;口服组恶心、呕吐、腹泻及中性粒细胞减少并发症更多。

关键数值与推荐

  • 主要终点为盲法独立中心审查根据RECIST 1.1评估的确认影像学缓解。
  • 次要终点包括无进展生存期和总生存期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intravenous paclitaxel (IVpac) is complicated by neuropathy and requires premedication to prevent hypersensitivity-type reactions. Paclitaxel is poorly absorbed orally; encequidar (E), a novel P-glycoprotein pump inhibitor, allows oral absorption. METHODS: A phase III open-label study comparing oral paclitaxel plus E (oPac + E) 205 mg/m2 paclitaxel plus 15 mg E methanesulfonate monohydrate 3 consecutive days per week versus IVpac 175 mg/m2 once every 3 weeks was performed. Women with metastatic breast cancer and adequate organ function, at least 1 year from last taxane, were randomly assigned 2:1 to oPac + E versus IVpac. The primary end point was confirmed radiographic response using RECIST 1.1, assessed by blinded independent central review. Secondary end points included progression-free survival (PFS) and overall survival (OS). RESULTS: Four hundred two patients from Latin America were enrolled (265 oPac + E, 137 IVpac); demographics and prior therapies were balanced. The confirmed response (intent-to-treat) was 36% for oPac + E versus 23% for IVpac (P = .01). The PFS was 8.4 versus 7.4 months, respectively (hazard ratio, 0.768; 95.5% CI, 0.584 to 1.01; P = .046), and the OS was 22.7 versus 16.5 months, respectively (hazard ratio, 0.794; 95.5% CI, 0.607 to 1.037; P = .08). Grade 3-4 adverse reactions were 55% with oPac + E and 53% with IVpac. oPac + E had lower incidence and severity of neuropathy (2% v 15% > grade 2) and alopecia (49% v 62% all grades) than IVpac but more nausea, vomiting, diarrhea, and neutropenic complications, particularly in patients with elevated liver enzymes. On-study deaths (8% oPac + E v 9% IVpac) were treatment-related in 3% and 0%, respectively. CONCLUSION: oPac + E increased the confirmed tumor response versus IVpac, with trends in PFS and OS. Neuropathy was less frequent and severe with oPac + E; neutropenic serious infections were increased. Elevated liver enzymes at baseline predispose oPac + E patients to early neutropenia and serious infections (funded by Athenex, Inc; ClinicalTrials.gov identifier: NCT02594371).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rugo HS, Umanzor GA, Barrios FJ, et al. Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. J Clin Oncol. 2022. PMID: 35858154. doi:10.1200/JCO.21.02953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。